Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Farnesyl pyrophosphate synthase (FPPS) is an established target for the treatment of bone diseases, but also shows promise as an anticancer and anti-infective drug target. Currently available anti-FPPS drugs are active-site-directed bisphosphonate inhibitors, the peculiar pharmacological profile of which is inadequate for therapeutic indications beyond bone diseases. The recent discovery of an allosteric binding site has paved the way toward the development of novel non-bisphosphonate FPPS inhibitors with broader therapeutic potential, notably as immunomodulators in oncology. Herein we report the discovery, by an integrated lead finding approach, of two new chemical classes of allosteric FPPS inhibitors that belong to the salicylic acid and quinoline chemotypes. We present their synthesis, biochemical and cellular activities, structure-activity relationships, and provide X-ray structures of several representative FPPS complexes. These novel allosteric FPPS inhibitors are devoid of any affinity for bone mineral and could serve as leads to evaluate their potential in none-bone diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cmdc.201500338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FPPS Downregulation Attenuates Endoplasmic Reticulum Stress in Pulmonary Epithelial Cells.
J Gene Med
June 2025
Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
The airway epithelium is the primary target of the trachea in lung transplant rejection and epithelial cell injury are frequently observed in lung transplants. Farnesyl pyrophosphate synthase (FPPS), a pivotal enzyme in the mevalonate pathway, synthesizes isoprenoid compounds like FPP and GGPP. This study found upregulated expression of FPPS in the epithelial cells of the tracheal transplant rat model and the use of the FPPS inhibitor zoledronic acid reduced the tracheal epithelial cell damage.
View Article and Find Full Text PDFPeptides as modulators of FPPS enzyme: A multifaceted evaluation from the design to the mechanism of action.
Eur J Med Chem
December 2024
Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 49, 80131, Naples, Italy. Electronic address:
Article Synopsis
- Bone diseases result from an imbalance in bone remodeling due to increased activity of osteoclasts and decreased activity of osteoblasts, and the mevalonate pathway (MVA) is essential for maintaining this equilibrium through the action of the enzyme FPPS.
- FDA-approved nitrogen-containing bisphosphonates (N-BPs) target FPPS, highlighting its importance in treating bone-related diseases, while recent research focuses on developing new FPPS inhibitors using a combination of computational modeling, biochemical assays, and biophysical techniques.
- The study demonstrates that newly designed peptides and phosphopeptides effectively inhibit FPPS, showcasing potential as anti-cancer agents by impacting the MVA pathway in murine colorectal cancer cells.
Nitrogen-containing bisphosphonate induces enhancement of OPG expression and inhibition of RANKL expression via inhibition of farnesyl pyrophosphate synthase to inhibit the osteogenic differentiation and calcification in vascular smooth muscle cells.
BMC Cardiovasc Disord
September 2024
Department of Nephrology, First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
Background: Nitrogen-containing bisphosphonate(N-BP)had been found to inhibit the osteogenic differentiation and calcification in vascular smooth muscle cells (VSMCs), but the mechanism is not clear. We intend to verify that N-BP induces enhancement of OPG expression and inhibition of RANKL expression via inhibition of farnesyl pyrophosphate synthase(FPPS) to inhibit the osteogenic differentiation and calcification in VSMCs.
Methods: β-glycerophosphate (β-GP) was used to induce the osteogenic differentiation and calcification in VSMCs.
Synthesis and preliminary anticancer evaluation of photo-responsive prodrugs of hydroxymethylene bisphosphonate alendronate.
Eur J Med Chem
April 2024
Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France. Electronic address:
The antitumoral activity of hydroxymethylene bisphosphonates (HMBP) such as alendronate or zoledronate is hampered by their exceptional bone-binding properties and their short plasmatic half-life which preclude their accumulation in non-skeletal tumors. In this context, the use of lipophilic prodrugs represents a simple and straightforward strategy to enhance the biodistribution of bisphosphonates in these tissues. We describe in this article the synthesis of light-responsive prodrugs of HMBP alendronate.
View Article and Find Full Text PDFStructural Insights into the Substrate Binding of Farnesyl Diphosphate Synthase FPPS1 from Silkworm, .
J Agric Food Chem
January 2024
Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Biological Science Research Center, Southwest University, Chongqing 400716, China.
Article Synopsis
- Farnesyl diphosphate synthase (FPPS) is key for the biosynthesis of juvenile hormones in insects, and this study presents the crystal structure of a type-I FPPS from Lepidoptera at 2.80 Å resolution.* -
- The analysis shows that FPPS1 has a unique α-helix structure with a deep central cavity and a distinct substrate-binding site compared to type-II FPPS, aiding in understanding how it binds to substrates.* -
- Additionally, RNA interference studies highlight the crucial roles of FPPSs in juvenile hormone production and the metamorphosis of larvae to pupae, particularly in silkworm development.*